120(top 100%)
PR articles
25.1K(top 1%)
PR citations
66(top 100%)
PR h-index
71(top 100%)
h-index
141
documents
31.5K
doc citations
2.6K
citing journals
100
times ranked

Publications

120 PR articles • 27,173 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | PR Citations
#ArticleIFPR CitationsLinks
1Novel biomarkers and strategies for HCC diagnosis and care
Clinical Liver Disease, 2024, 23,
1.42Citations (PDF)
2Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Gut, 2023, 72, 129-140
21.2194Citations (PDF)
3Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Gut, 2023, 72, 736-748
21.2120Citations (PDF)
4WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma
Nature Cancer, 2023, 4, 1157-1175
22.823Citations (PDF)
5Biomarkers for immunotherapy of hepatocellular carcinoma
Nature Reviews Clinical Oncology, 2023, 20, 780-798
75.5164Citations (PDF)
6Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer
Gut, 2022, 71, 2069-2080
21.239Citations (PDF)
7Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy
Talanta, 2022, 241, 123256
5.926Citations (PDF)
8Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma
Molecular Oncology, 2022, 16, 665-682
4.29Citations (PDF)
9Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Clinical Cancer Research, 2022, 28, 2297-2305
6.913Citations (PDF)
10Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Nature Cancer, 2022, 3, 386-401
22.8382Citations (PDF)
11Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma
Seminars in Liver Disease, 2022, 42, 188-201
3.410Citations (PDF)
12DNA Methylation Profiling of Human Hepatocarcinogenesis
Hepatology, 2021, 74, 183-199
10.682Citations (PDF)
13Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Hepatology, 2021, 73, 158-191
10.6342Citations (PDF)
14Biomarkers for Hepatobiliary Cancers
Hepatology, 2021, 73, 115-127
10.6136Citations (PDF)
15The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication
Cancers, 2021, 13, 659
4.041Citations (PDF)
16Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone‐Dependent Release of Circulating Tumor DNA
Hepatology Communications, 2021, 5, 1095-1105
4.77Citations (PDF)
17Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma
PLoS Genetics, 2021, 17, e1009589
3.320Citations (PDF)
18Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis
JHEP Reports, 2021, 3, 100237
4.858Citations (PDF)
19Novel non-protein biomarkers for early detection of hepatocellular carcinoma
Engineering, 2021, ,
7.92Citations (PDF)
20Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
Gastroenterology, 2021, 161, 879-898
1.0209Citations (PDF)
21Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B
JHEP Reports, 2021, 3, 100364
4.822Citations (PDF)
22Hepatocellular carcinoma
Nature Reviews Disease Primers, 2021, 7,
50.75,235Citations (PDF)
23Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing
BMC Medicine, 2020, 18,
7.534Citations (PDF)
24Liquid biopsy in the clinical management of hepatocellular carcinoma
Gut, 2020, 69, 2025-2034
21.2107Citations (PDF)
25Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors
Scientific Reports, 2020, 10,
3.56Citations (PDF)
26Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Journal of Hepatology, 2020, 73, 315-327
3.6257Citations (PDF)
27Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma
Liver Transplantation, 2020, 26, 823-831
2.634Citations (PDF)
28Intratumoral heterogeneity and clonal evolution in liver cancer
Nature Communications, 2020, 11,
13.9318Citations (PDF)
29Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
Oncogene, 2020, 40, 140-151
6.7112Citations (PDF)
30Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Gut, 2019, 68, 1065-1075
21.2287Citations (PDF)
31Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
British Journal of Cancer, 2019, 121, 340-343
5.778Citations (PDF)
32Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Cancer Research, 2019, 79, 4326-4330
0.6137Citations (PDF)
33Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma
Clinical Liver Disease, 2019, 14, 62-65
1.425Citations (PDF)
34A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites
Histopathology, 2019, 74, 718-730
3.710Citations (PDF)
35Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Molecular Cancer Therapeutics, 2019, 18, 1506-1519
1.820Citations (PDF)
36The oncogenic role of hepatitis delta virus in hepatocellular carcinoma
JHEP Reports, 2019, 1, 120-130
4.867Citations (PDF)
37β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Cancer Discovery, 2019, 9, 1124-1141
25.6770Citations (PDF)
38Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans
Hepatology, 2019, 70, 2107-2122
10.630Citations (PDF)
39Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2
Breast Cancer Research, 2019, 21,
4.922Citations (PDF)
40Hepatocellular Carcinoma
New England Journal of Medicine, 2019, 380, 1450-1462
43.73,948Citations (PDF)
41The Impact of Translational Research in Hepatology
Clinical Liver Disease, 2019, 13, 29-33
1.42Citations (PDF)
42Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Journal of Hepatology, 2019, 70, 1262-1277
3.6199Citations (PDF)
43Tumour evolution in hepatocellular carcinoma
Nature Reviews Gastroenterology and Hepatology, 2019, 17, 139-152
48.0707Citations (PDF)
44A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
Oncogene, 2018, 37, 3740-3752
6.7102Citations (PDF)
45Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma
Oncoscience, 2018, 5, 209-211
1.312Citations (PDF)
46High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma
Scientific Reports, 2018, 8,
3.574Citations (PDF)
47Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
Gut, 2017, 66, 530-540
21.2187Citations (PDF)
48Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity
Journal of Hepatology, 2017, 66, 952-961
3.6151Citations (PDF)
49Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Gastroenterology, 2017, 153, 812-826
1.0815Citations (PDF)
50Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Gastroenterology, 2017, 152, 745-761
1.01,029Citations (PDF)
51Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma
Journal of Hepatology, 2017, 67, 1222-1231
3.6151Citations (PDF)
52Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease‐hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective
Clinical Liver Disease, 2016, 8, 100-104
1.421Citations (PDF)
53Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition
Cancer Cell, 2016, 30, 879-890
38.5194Citations (PDF)
54The transition from inflammation to cancer in the liver
Clinical Liver Disease, 2016, 8, 89-93
1.434Citations (PDF)
55IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models
Gastroenterology, 2016, 151, 1192-1205
1.0116Citations (PDF)
56Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Journal of Hepatology, 2016, 65, 1031-1042
3.6271Citations (PDF)
57Liver capsule: Molecular‐based signatures in hepatocellular carcinoma
Hepatology, 2016, 63, 2018-2018
10.69Citations (PDF)
58A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection
Gut, 2016, 65, 1754-1764
21.2125Citations (PDF)
59Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015
Journal of Hepatology, 2016, 64, 1428-1445
3.63Citations (PDF)
60Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Nature Reviews Clinical Oncology, 2015, 12, 408-424
75.5513Citations (PDF)
61DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Hepatology, 2015, 61, 1945-1956
10.6420Citations (PDF)
62Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma
Gastroenterology, 2015, 148, 806-818.e10
1.0118Citations (PDF)
63Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Gastroenterology, 2015, 149, 1226-1239.e4
1.01,171Citations (PDF)
64Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015
Journal of Hepatology, 2015, 63, 753-762
3.65Citations (PDF)
65DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Clinical Cancer Research, 2015, 21, 925-933
6.980Citations (PDF)
66Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma
Clinical Cancer Research, 2015, 21, 1786-1788
6.984Citations (PDF)
67The Future of Patient-Derived Tumor Xenografts in Cancer Treatment
Pharmacogenomics, 2015, 16, 1671-1683
1.646Citations (PDF)
68A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
Gut, 2015, 64, 1296-1302
21.275Citations (PDF)
69The usual SASPects of liver cancer
Aging, 2015, 7, 348-349
2.55Citations (PDF)
70UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma
Cancer Cell, 2014, 25, 196-209
38.5288Citations (PDF)
71VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design, 2014, 20, 2834-2842
2.483Citations (PDF)
72Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis
Gastroenterology, 2013, 144, 1024-1030
1.0217Citations (PDF)
73Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with<i>EGFR</i>
Hepatology, 2013, 57, 120-130
10.654Citations (PDF)
74Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach
Journal of Hepatology, 2013, 59, 392-395
3.620Citations (PDF)
75Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Gastroenterology, 2013, 144, 829-840
1.0505Citations (PDF)
76A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Gastroenterology, 2013, 145, 176-187
1.0317Citations (PDF)
77Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension
World Journal of Gastroenterology, 2013, 19, 1193
4.835Citations (PDF)
78Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma
Hepatology, 2012, 56, 2416-2419
10.616Citations (PDF)
79Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
Clinical Cancer Research, 2012, 18, 4997-5007
6.9284Citations (PDF)
80Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma
Journal of Hepatology, 2012, 56, 1198-1200
3.63Citations (PDF)
81Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps
Journal of Hepatology, 2012, 57, 213-214
3.66Citations (PDF)
82Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
Journal of Hepatology, 2012, 56, 1343-1350
3.6196Citations (PDF)
83Why men are at higher risk for hepatocellular carcinoma?
Journal of Hepatology, 2012, 57, 453-454
3.648Citations (PDF)
84Pronóstico genómico en el carcinoma hepatocelular
Gastroenterología Y Hepatología, 2012, 35, 94-101
0.62Citations (PDF)
85Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Clinical Cancer Research, 2012, 18, 1824-1826
6.988Citations (PDF)
86Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing
Hepatology, 2012, 56, 1361-1370
10.634Citations (PDF)
87Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Gastroenterology, 2012, 143, 1660-1669.e7
1.0296Citations (PDF)
88Gene Signatures in the Management of Hepatocellular Carcinoma
Seminars in Oncology, 2012, 39, 473-485
1.970Citations (PDF)
89Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Nature Reviews Gastroenterology and Hepatology, 2012, 10, 34-42
48.0290Citations (PDF)
90Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma
Gastroenterology, 2011, 140, 1501-1512.e2
1.0420Citations (PDF)
91MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a
Gastroenterology, 2011, 140, 1618-1628.e16
1.0212Citations (PDF)
92Targeted Therapies for Hepatocellular Carcinoma
Gastroenterology, 2011, 140, 1410-1426
1.0429Citations (PDF)
93Gene-expression signature of vascular invasion in hepatocellular carcinoma
Journal of Hepatology, 2011, 55, 1325-1331
3.6140Citations (PDF)
94Depicting the role of TP53 in hepatocellular carcinoma progression
Journal of Hepatology, 2011, 55, 724-725
3.663Citations (PDF)
95Molecular Pathogenesis of Hepatocellular Carcinoma
Alcoholism: Clinical and Experimental Research, 2011, 35, 821-825
2.648Citations (PDF)
96Carcinogen-induced hepatic tumors in KLF6+/− mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation
Hepatology, 2011, 54, 522-531
10.642Citations (PDF)
97Inherited hepatocellular carcinoma
Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 725-734
3.028Citations (PDF)
98New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
Clinical Cancer Research, 2010, 16, 4688-4694
6.9116Citations (PDF)
99Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Seminars in Liver Disease, 2010, 30, 035-051
3.4280Citations (PDF)
100Cancer gene discovery in hepatocellular carcinoma
Journal of Hepatology, 2010, 52, 921-929
3.6179Citations (PDF)
101IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
Journal of Hepatology, 2010, 52, 550-559
3.6215Citations (PDF)
102Genomic tracing of the elusive liver cancer ancestor
Journal of Hepatology, 2010, 53, 578-579
3.61Citations (PDF)
103Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Annual Review of Medicine, 2010, 61, 317-328
19.5242Citations (PDF)
104Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
Cancer Research, 2009, 69, 7385-7392
0.61,131Citations (PDF)
105A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma
Nature Biotechnology, 2009, 27, 264-274
32.2199Citations (PDF)
106Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Journal of Hepatology, 2009, 51, 725-733
3.6213Citations (PDF)
107Pathogenesis of hepatocellular carcinoma and molecular therapies
Current Opinion in Gastroenterology, 2009, 25, 186-194
2.3121Citations (PDF)
108Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression
Journal of Clinical Investigation, 2009, 119, 465-477
10.7307Citations (PDF)
109Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma
Gastroenterology, 2008, 134, 1521-1531
1.099Citations (PDF)
110Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Gastroenterology, 2008, 135, 1972-1983.e11
1.0680Citations (PDF)
111Experimental models of hepatocellular carcinoma
Journal of Hepatology, 2008, 48, 858-879
3.6211Citations (PDF)
112Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Molecular Cancer Therapeutics, 2008, 7, 3129-3140
1.81,346Citations (PDF)
113Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
New England Journal of Medicine, 2008, 359, 1995-2004
43.71,201Citations (PDF)
114Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps
Current Opinion in Oncology, 2008, 20, 444-453
2.261Citations (PDF)
115Genomics and Signaling Pathways in Hepatocellular Carcinoma
Seminars in Liver Disease, 2007, 27, 055-076
3.4499Citations (PDF)
116Current management of liver cancer
European Journal of Cancer, Supplement, 2007, 5, 444-446
0.54Citations (PDF)
117Biología celular y genética en el cáncer de hígado
Gastroenterología Y Hepatología, 2007, 30, 360-369
0.65Citations (PDF)
118A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis
Gastroenterology, 2006, 131, 1758-1767
1.0385Citations (PDF)
119Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions
European Journal of Gastroenterology and Hepatology, 2006, 18, 79-83
1.424Citations (PDF)
120Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal
Liver Transplantation, 2006, 12, 1747-1754
2.617Citations (PDF)